DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.

被引：3
|
作者：
Yoon, Jee Sun
Kim, Jin Won
Kim, Ji-Won
Kim, Tae-Yong
Nam, Ah-Rong
Bang, Ju-Hee
Seo, Hye-Rim
Kim, Jae-Min
Oh, Kyoung Seok
Mortimer, Peter G.
Smith, Simon
Oh, Do-Youn
机构：
[1] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Internal Med, Seongnam, South Korea
[3] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea
[4] AstraZeneca, R&D Oncol, Early Oncol Clin Sci, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS4166
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4166
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Results from a phase I, open-label study of ceralasertib (AZD6738), a novel DNA damage repair agent, in combination with weekly paclitaxel in refractory cancer (NCT02630199).
    Lee, Jeeyun
    Kim, Seung Tae
    Smith, Simon
    Mortimer, Peter G.
    Loembe, Bienvenu
    Hong, Jung
    Kozarewa, Iwanka
    Pierce, Andrew
    Dean, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [12] Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress
    Oh, Do-Youn
    Kim, Jin Won
    Chon, Hongjae
    Lee, Choong-Kun
    Kim, Ji-Won
    Kang, Beodeul
    Choi, Hye Jin
    Park, Se Jun
    Yoon, Jeesun
    Lee, Myung Ah
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [13] The DORA trial: A non-comparator randomised phase II multi-center maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum treated advanced triple negative breast cancer (TNBC)
    Dent, Rebecca
    Tan, Tira
    Kim, Sung-Bae
    Traina, Tiffany
    McArthur, Heather
    Im, Young-Hyuck
    Creel, Trish
    Blackwell, Kimberly
    CANCER RESEARCH, 2018, 78 (04)
  • [14] Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study
    Jing, Chao
    Bai, Zhigang
    Tong, Kuinan
    Yang, Xiaobao
    Liu, Kun
    Wu, Hongwei
    Zhu, Jiegao
    Guo, Wei
    Zhang, Zhongtao
    Deng, Wei
    ONCOLOGIST, 2024, 29 (11): : e1565 - e1574
  • [15] Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment
    Richard Kim
    E Gabriela Chiorean
    Manik Amin
    Caio Max S Rocha-Lima
    Jitendra Gandhi
    William P Harris
    Tao Song
    David Portnoy
    British Journal of Cancer, 2017, 117 : 189 - 194
  • [16] Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment
    Kim, Richard
    Chiorean, E. Gabriela
    Amin, Manik
    Rocha-Lima, Caio Max S.
    Gandhi, Jitendra
    Harris, William P.
    Song, Tao
    Portnoy, David
    BRITISH JOURNAL OF CANCER, 2017, 117 (02) : 189 - 194
  • [17] Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial
    Valle, Juan W.
    Wasan, Harpreet
    Lopes, Andre
    Backen, Alison C.
    Palmer, Daniel H.
    Morris, Karen
    Duggan, Marian
    Cunningham, David
    Anthoney, D. Alan
    Corrie, Pippa
    Madhusudan, Srinivasan
    Maraveyas, Anthony
    Ross, Paul J.
    Waters, Justin S.
    Steward, Will P.
    Rees, Charlotte
    Beare, Sandy
    Dive, Caroline
    Bridgewater, John A.
    LANCET ONCOLOGY, 2015, 16 (08): : 967 - 978
  • [18] Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)
    Leone, Francesco
    Marino, Donatella
    Cereda, Stefano
    Filippi, Roberto
    Belli, Carmen
    Spadi, Rosella
    Nasti, Guglielmo
    Montano, Massimo
    Amatu, Alessio
    Aprile, Giuseppe
    Cagnazzo, Celeste
    Fasola, Gianpiero
    Siena, Salvatore
    Ciuffreda, Libero
    Reni, Michele
    Aglietta, Massimo
    CANCER, 2016, 122 (04) : 574 - 581
  • [19] A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress
    Jani, Chinmay
    Xie, Wanling
    Ajmera, Archana
    Araneta, Arlene
    Jamieson, Christina
    Folefac, Edmund
    Hussain, Arif
    Kyriakopoulos, Christos
    Olson, Adam C.
    Parikh, Mamta
    Parikh, Rahul Atul
    Saraiya, Biren
    Jabbour, Salma K.
    Ivy, S. Percy
    Van Allen, Eliezer Mendel
    Lindeman, Neal Ian
    Kochupurakkal, Bose
    Shapiro, Geoffrey
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [20] Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study
    Oh, Do-Youn
    Lee, Kyung-Hun
    Lee, Dae-Won
    Yoon, Jeesun
    Kim, Tae-Yong
    Bang, Ju-Hee
    Nam, Ah-Rong
    Oh, Kyoung-Seok
    Kim, Jae-Min
    Lee, Young
    Guthrie, Violeta
    McCoon, Patricia
    Li, Weimin
    Wu, Song
    Zhang, Qu
    Rebelatto, Marlon C.
    Kim, Jin Won
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (06): : 522 - 532
12345